Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study

BMC Psychiatry

Volumn 13, Issue , 2013, Pages

  Katagiri, Hideaki ^a   Tohen, Mauricio ^b   McDonnell, David P ^c   Fujikoshi, Shinji ^a   Case, Michael ^c   Kanba, Shigenobu ^d,e   Takahashi, Michihiro ^a,f   Gomez, Juan Carlos ^c  

^a Lilly Research Laboratories   (Japan)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d KYUSHU UNIVERSITY   (Japan)

^e East Asian Bipolar Forum   (Japan)

^f Terauchi Takahashi Psychiatric Clinic   (Japan)

Author keywords

Bipolar depression; Bipolar disorder; Efficacy; Japan; Japanese; Monotherapy; Olanzapine; Safety

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; PLACEBO; TRIACYLGLYCEROL;

17 ITEM HAMILTON DEPRESSION RATING SCALE; ADULT; APPETITE DISORDER; ARTICLE; BIPOLAR DEPRESSION; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSIONS BIPOLAR VERSION SEVERITY OF ILLNESS SCALE; CONCENTRATION LOSS; CONTROLLED STUDY; CONVALESCENCE; DEPRESSION; DIET RESTRICTION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOKALEMIC PERIODIC PARALYSIS; JAPANESE; LASSITUDE; MAJOR CLINICAL STUDY; MALE; MANIA; MENTAL PATIENT; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PESSIMISM; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUICIDAL IDEATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL; YOUNG MANIA RATING SCALE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BENZODIAZEPINES; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84878381705     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-13-138     Document Type: Article

References (28)

1. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zarkov Z. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011, 68:241-251. 10.1001/archgenpsychiatry.2011.12, 3486639, 21383262.
2. Bowden CL. The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder. Neuropsychiatr Dis Treat 2011, 7:87-92. 3083981, 21552310.
3. Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valenti M, Vieta E. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol 2010, 13:5-14. 10.1017/S1461145709990344, 19638254.
4. Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 2011, 199:57-63. 10.1192/bjp.bp.110.084822, 21593515.
5. Erfurth A, Michael N, Stadtland C, Arolt V. Bupropion as add-on strategy in difficult-to-treat bipolar depressive patients. Neuropsychobiology 2002, 45(Suppl 1):33-36.
6. Pilhatsch M, Wolf R, Winter C, Lewitzka U, Bauer M. Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: a reanalysis of a randomized, double-blind study. J Affect Disord 2010, 126:453-457. 10.1016/j.jad.2010.04.025, 20547424.
7. Calabrese JR, Keck PE, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005, 162:1351-1360. 10.1176/appi.ajp.162.7.1351, 15994719.
8. Thase ME, Bowden CL, Nashat M, Eudicone JM, Marcus R, McQuade RD, Carlson BX. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006, 26:600-609. 10.1097/01.jcp.0000248603.76231.b7, 17110817.
9. Quante A, Zeugmann S, Luborzewski A, Schommer N, Langosch J, Born C, Anghelescu I, Wolf J. Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study. Hum Psychopharmacol 2010, 25:126-132. 10.1002/hup.1096, 20196183.
10. Yatham LN. A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder. J Affect Disord 2011, 128(Suppl 1):S21-S28.
11. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus RN, Owen R. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008, 28:13-20. 10.1097/jcp.0b013e3181618eb4, 18204335.
12. Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vanderburg DG, Kasuba B. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011, 72:1413-1422. 10.4088/JCP.09m05934, 21672493.
13. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003, 60:1079-1088. 10.1001/archpsyc.60.11.1079, 14609883.
14. Tohen M, McDonnell DP, Case M, Kanba S, Ha K, Fang YR, Katagiri H, Gomez JC. Randomized, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry 2012, 201:376-382. 10.1192/bjp.bp.112.108357, 22918966.
15. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389. 10.1192/bjp.134.4.382, 444788.
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62. 10.1136/jnnp.23.1.56, 495331, 14399272.
17. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-435. 10.1192/bjp.133.5.429, 728692.
18. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997, 73:159-171. 10.1016/S0165-1781(97)00123-6, 9481807.
19. Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN, Malhi GS, Calabrese JR, Nolen WA, Vieta E, Kapczinski F, Goodwin GM, Suppes T, Sachs GS, Chengappa KR, Grunze H, Mitchell PB, Kanba S, Berk M. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009, 11:453-473. 10.1111/j.1399-5618.2009.00726.x, 19624385.
20. Kim JH, Jung HY, Kang UG, Jeong SH, Ahn YM, Byun HJ, Ha KS, Kim YS. Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders. Mov Disord 2002, 17:1354-1359. 10.1002/mds.10255, 12465082.
21. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl 20):22-33.
22. Thase ME, Bowden CL, Nashat M, Eudicone JM, Marcus R, McQuade RD, Carlson BX. Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms. Int J Psychiatry Clin Pract 2012, 16:121-131. 10.3109/13651501.2011.632680, 22296512.
23. Bech P, Tanghoj P, Andersen HF, Overo K. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berl) 2002, 163:20-25.
24. Benazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. J Clin Psychiatry 2009, 70:1424-1431. 10.4088/JCP.08m04772gre, 19906346.
25. Kemp AS, Schooler NR, Kalali AH, Alphs L, Anand R, Awad G, Davidson M, Dubé S, Ereshefsky L, Gharabawi G, Leon AC, Lepine JP, Potkin SG, Vermeulen A. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?. Schizophr Bull 2010, 36:504-509. 10.1093/schbul/sbn110, 2879679, 18723840.
26. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002, 287:1840-1847. 10.1001/jama.287.14.1840, 11939870.
27. Katagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M. Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study. J Affect Disord 2012, 136:476-484. 10.1016/j.jad.2011.10.045, 22134043.
28. Zyprexa [package insert] 2008, Indianapolis, IN: Eli Lilly and Company.